Lv1
50 积分 2025-09-08 加入
Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model
2个月前
已完结
In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
6个月前
已完结
Safety and efficacy of CRISPR-mediated genome ablation of VEGFA as a treatment for choroidal neovascularization in nonhuman primate eyes
8个月前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
11个月前
已完结
[Expert opinions on the technical guiding principles for clinical trials of drugs in the treatment of chronic hepatitis B virus infection]
11个月前
已完结
DGAT2 reduction and lipid dysregulation drive psoriasis development in keratinocyte-specific SPRY1-deficient mice
1年前
已完结
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study
1年前
已完结
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
1年前
已完结
Therapeutic opportunities for the treatment of NASH with genetically validated targets
1年前
已完结
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials
1年前
已完结
皖公网安备34019202002308
